An official website of the United States government
NIH Websites Are Changing Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Trial Status: active
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and
antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with
advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring
KRAS mutations.
Inclusion Criteria
Pathologically confirmed diagnosis of metastatic Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) with evidence of a single KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA).
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
Patients must have received all standard therapies for their cancer type in the metastatic setting, unless they are unable to receive such therapies due to clinical characteristics, comorbidities, or other medically justified reasons.
Exclusion Criteria
History of additional malignancy within the last 2 years, with some exceptions as specified in the protocol.
Active brain metastases (participants with asymptomatic brain metastases may be eligible).
Have received prior targeted treatment(s) against KRAS, including pan-KRAS inhibitors, multi-RAS inhibitors, mutant-selective KRAS inhibitors, and RAS or KRAS degraders.
Active or uncontrolled systemic infection, such as tuberculosis, Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV). The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07629960.
Locations matching your search criteria
United States
Massachusetts
Boston
Massachusetts General Hospital Cancer Center
Status: Active
Name Not Available
Dana-Farber Harvard Cancer Center
Status: Active
Name Not Available
Texas
Houston
UT MD Anderson Cancer Center
Status: Active
Name Not Available
This is an open-label, multi-center, Phase 1/2 study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), and efficacy of BLU-924, a pan-KRAS inhibitor, in
participants with metastatic KRAS mutant pancreatic ductal adenocarcinoma (PDAC),
non-small cell lung cancer (NSCLC), or colorectal cancer (CRC). The monotherapy part of
the study includes Dose Escalation, Dose Enrichment, and Dose Expansion. Participants
enrolled during Dose Escalation and Dose Enrichment will be evaluated for dose limiting
toxicities (DLTs) to determine the MTD. Participants enrolled into disease-specific
Enrichment cohorts will enable a more robust characterization of safety, PK,
pharmacodynamics, and preliminary clinical activity. Enrolment into Dose Expansion will
follow the identification of at least 1 recommended dose for expansion (RDFE) based on
data from the Dose Escalation and Dose Enrichment. No combination arm is active at this